斑块型银屑病-话题@MedSci

#斑块型银屑病#

36篇内容 | 2135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1490378, encodeId=d81714903e8bb, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, objectType=article, longId=177305, objectId=15131e730596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15131e730596, replyNumber=0, likeNumber=54, createdTime=2019-08-10, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15131e730596, moduleTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15131e730596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490377, encodeId=564314903e7e3, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应, objectType=article, longId=162064, objectId=ec44162064e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec44162064e5, replyNumber=0, likeNumber=116, createdTime=2019-03-12, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec44162064e5, moduleTitle=美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec44162064e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=75, createdTime=2019-03-03, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490375, encodeId=cc4214903e56b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=74, createdTime=2019-03-02, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490374, encodeId=6da014903e4e6, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=2018 欧洲专家共识：临床应用富马酸二甲酯治疗中重度斑块型银屑病, objectType=article, longId=150066, objectId=4ac0150066b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ac0150066b7, replyNumber=0, likeNumber=47, createdTime=2018-10-01, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ac0150066b7, moduleTitle=2018 欧洲专家共识：临床应用富马酸二甲酯治疗中重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ac0150066b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490373, encodeId=0c4a14903e3bf, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=68, createdTime=2018-09-13, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490372, encodeId=9a0914903e297, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=FDA扩大Cimzia的适应症：中度至重度斑块型银屑病, objectType=article, longId=139445, objectId=c77e139445ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77e139445ee, replyNumber=0, likeNumber=57, createdTime=2018-05-31, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77e139445ee, moduleTitle=FDA扩大Cimzia的适应症：中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77e139445ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490371, encodeId=8edd14903e1e0, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=2018 亚洲共识：轻中度斑块型银屑病局部治疗的评估和管理, objectType=article, longId=138014, objectId=ec09138014d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec09138014d9, replyNumber=0, likeNumber=72, createdTime=2018-05-14, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec09138014d9, moduleTitle=2018 亚洲共识：轻中度斑块型银屑病局部治疗的评估和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec09138014d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490370, encodeId=10ee14903e0e9, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优, objectType=article, longId=114695, objectId=84bc114695d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84bc114695d0, replyNumber=0, likeNumber=77, createdTime=2017-09-30, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84bc114695d0, moduleTitle=Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84bc114695d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490369, encodeId=852014903697f, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, objectType=article, longId=101021, objectId=091a10102187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091a10102187, replyNumber=0, likeNumber=83, createdTime=2017-06-09, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091a10102187, moduleTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091a10102187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490368, encodeId=af091490368da, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Lancet：阿达木单抗用于重度斑块型银屑病的儿童和青少年患者, objectType=article, longId=97948, objectId=52f99e94828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52f99e94828, replyNumber=0, likeNumber=79, createdTime=2017-05-07, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52f99e94828, moduleTitle=Lancet：阿达木单抗用于重度斑块型银屑病的儿童和青少年患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52f99e94828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490367, encodeId=60fa149036eea, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, objectType=article, longId=85676, objectId=152b856e6bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152b856e6bf, replyNumber=0, likeNumber=64, createdTime=2016-12-29, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152b856e6bf, moduleTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=152b856e6bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490366, encodeId=c6091490366ea, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案, objectType=article, longId=85088, objectId=aef18508830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aef18508830, replyNumber=0, likeNumber=98, createdTime=2016-12-23, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aef18508830, moduleTitle=Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aef18508830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490365, encodeId=c29a149036588, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布, objectType=article, longId=81033, objectId=f6618103358, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6618103358, replyNumber=0, likeNumber=46, createdTime=2016-10-27, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6618103358, moduleTitle=2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6618103358)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490364, encodeId=63b4149036406, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=FDA受理安进重磅抗炎药Enbrel儿科斑块型银屑病申请, objectType=article, longId=64868, objectId=7ba66486882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ba66486882, replyNumber=0, likeNumber=85, createdTime=2016-03-17, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ba66486882, moduleTitle=FDA受理安进重磅抗炎药Enbrel儿科斑块型银屑病申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ba66486882)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490363, encodeId=a4a91490363e2, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=NEJM：Guselkumab和阿达木单抗治疗斑块型银屑病, objectType=article, longId=53133, objectId=bda753133e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bda753133e1, replyNumber=0, likeNumber=90, createdTime=2015-07-11, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bda753133e1, moduleTitle=NEJM：Guselkumab和阿达木单抗治疗斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bda753133e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490362, encodeId=fd36149036250, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Lancet：托法替尼和依那西普治疗中重度斑块型银屑病, objectType=article, longId=51736, objectId=198051e3631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=198051e3631, replyNumber=0, likeNumber=58, createdTime=2015-06-07, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=198051e3631, moduleTitle=Lancet：托法替尼和依那西普治疗中重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=198051e3631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490361, encodeId=73ab14903617b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, objectTitle=Otezla可能被欧盟批准用于斑块型银屑病治疗, objectType=article, longId=43285, objectId=d2394328540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2394328540, replyNumber=0, likeNumber=88, createdTime=2014-11-30, rootId=0, userName=zz73, userId=435a8732843, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2394328540, moduleTitle=Otezla可能被欧盟批准用于斑块型银屑病治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2394328540)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

斑块型银屑病

2020-05-29

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组

2019-08-10

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应

2019-03-12

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病

2019-03-02

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

2018 欧洲专家共识：临床应用富马酸二甲酯治疗中重度斑块型银屑病

2018-10-01

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-09-13

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

FDA扩大Cimzia的适应症：中度至重度斑块型银屑病

2018-05-31

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

2018 亚洲共识：轻中度斑块型银屑病局部治疗的评估和管理

2018-05-14

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Br J Dermatol：Guselkumab治疗不同亚群的中度至重度斑块型银屑病，疗效依然较优

2017-09-30

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病

2017-06-09

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Lancet：阿达木单抗用于重度斑块型银屑病的儿童和青少年患者

2017-05-07

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病

2016-12-29

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案

2016-12-23

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布

2016-10-27

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

FDA受理安进重磅抗炎药Enbrel儿科斑块型银屑病申请

2016-03-17

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

NEJM：Guselkumab和阿达木单抗治疗斑块型银屑病

2015-07-11

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Lancet：托法替尼和依那西普治疗中重度斑块型银屑病

2015-06-07

zz73 (审核中...)

前往app查看评论内容

#斑块型银屑病#

Otezla可能被欧盟批准用于斑块型银屑病治疗

2014-11-30

科室
- - 订阅+
  - 更多科室
工具
服务